Takeda’s New Drug for Ulcerative Colitis and Crohn’s Seen As Promising Treatment

Takeda’s New Drug for Ulcerative Colitis and Crohn’s Seen As Promising Treatment
The recent FDA and European Commission approvals of Takeda Pharmaceuticals’ drug Entyvio for the treatment of ulcerative colitis and Crohn’s disease has given doctors and patients a promising new therapeutic option to tackle these diseases. As described by the largest pharmaceutical company in Japan, “ulcerative colitis (UC) and Crohn’s disease (CD) are marked by inflammation in the lining

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *